Trade Mark Journal No.2025/037 12 September 2025

UK00004251358 19 August 2025 (5,42)

K2 THERAPEUTICS

International priority date claimed: 26 February 2025 (Singapore) (40202504501S)

Class 5: Pharmaceutical products for the prevention and treatment of disease, namely, cancer, autoimmune diseases and immunological diseases; therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases and immunological diseases; pharmaceuticals being medicines comprised of small molecules, cell therapies, nucleic acids and biologics for treatment of cancer, autoimmune diseases and immunological diseases; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases and immunological diseases, and for use in the fields of oncology, auto-immunity and immunology.
Class 42: Pharmaceutical research and development; scientific research and development; medical research; development in the field of medical products and preparations; medical research, development, manufacturing and commercialization services in the fields of drug discovery, oncology, auto-immunity and immunology; development of manufacturing methods for others for pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases and immunological diseases, and for use in the fields of oncology, auto-immunity and immunology.

K2 Therapeutics Pte. Ltd.

Representative: Morgan, Lewis & Bockius UK LLP